Melissa Weber


How Important Is CYP2D6 Status in Hormone-Sensitive Cancers?

December 09, 2010

In recent years, scientists discovered that an enzyme called CYP2D6 could possibly predict whether a patient would respond to the drug. Small studies aimed at confirming the predictive link, however, have been consistently inconsistent.

Afinitor Boosts Effectiveness of Hormonal Therapy

December 09, 2010

Adding Afinitor, an mTOR inhibitor, to tamoxifen helped women with metastatic breast cancer live about four months longer without their disease getting worse, according to a study presented Thursday at SABCS.

Preventing Cancer in BRCA Mutation Carriers

December 08, 2010

Every woman with a mutated BRCA1 or BRCA2 gene should have their ovaries removed to lower their risk of ovarian cancer, said Susan Domchek, MD, one of the educational sessions speakers at the 2010 SABCS.

Tasigna and Sprycel Outshine Gleevec

September 07, 2010

Oncologists have begun trading in what had become a miracle pill for patients with chronic myeloid leukemia for more potent, newer-generation drugs that appear to work even better as first-line treatment for CML.

New Breast Cancer Drug Extends Lives of Metastatic Patients

June 16, 2010

A new chemotherapy drug, called eribulin, extended survival by two and a half months in patients with locally recurrent or metastatic breast cancer whose cancers continued to progress despite treatment with numerous other drugs.

Longer Use of Avastin Slows Ovarian Cancer

June 15, 2010

Continued use of the targeted drug Avastin (bevacizumab), after initial treatment with the drug and chemotherapy, helped slow progression of advanced ovarian cancer, according to a phase 3 study.

Immunotherapy Drug Extends Survival in Metastatic Melanoma

June 14, 2010

For metastatic melanoma patients who were out of treatment options, the immune system-targeted drug ipilimumab extended their lives by nearly four months compared with an investigational vaccine called gp100.